{
     "PMID": "15050644",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20041109",
     "LR": "20051117",
     "IS": "0960-894X (Print) 0960-894X (Linking)",
     "VI": "14",
     "IP": "8",
     "DP": "2004 Apr 19",
     "TI": "(S)-N-[1-(4-cyclopropylmethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-ethyl]-3-(2-f luoro-phenyl)-acrylamide is a potent and efficacious KCNQ2 opener which inhibits induced hyperexcitability of rat hippocampal neurons.",
     "PG": "1991-5",
     "AB": "(S)-N-[1-(4-Cyclopropylmethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-ethyl]-3-(2-f luoro-phenyl)-acrylamide ((S)-2) was identified as a potent and efficacious KCNQ2 opener. This compound demonstrated significant activity in reducing neuronal hyperexcitability in rat hippocampal slices, and the inhibition mediated by (S)-2 was reversed by the KCNQ blocker linopirdine.",
     "FAU": [
          "Wu, Yong-Jin",
          "Boissard, Christopher G",
          "Chen, Jie",
          "Fitzpatrick, William",
          "Gao, Qi",
          "Gribkoff, Valentin K",
          "Harden, David G",
          "He, Huan",
          "Knox, Ronald J",
          "Natale, Joanne",
          "Pieschl, Rick L",
          "Starrett, John E Jr",
          "Sun, Li-Qiang",
          "Thompson, Mark",
          "Weaver, David",
          "Wu, Dedong",
          "Dworetzky, Steven I"
     ],
     "AU": [
          "Wu YJ",
          "Boissard CG",
          "Chen J",
          "Fitzpatrick W",
          "Gao Q",
          "Gribkoff VK",
          "Harden DG",
          "He H",
          "Knox RJ",
          "Natale J",
          "Pieschl RL",
          "Starrett JE Jr",
          "Sun LQ",
          "Thompson M",
          "Weaver D",
          "Wu D",
          "Dworetzky SI"
     ],
     "AD": "Department of Neuroscience Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA. yong-jin.wu@bms.com",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article"
     ],
     "PL": "England",
     "TA": "Bioorg Med Chem Lett",
     "JT": "Bioorganic & medicinal chemistry letters",
     "JID": "9107377",
     "RN": [
          "0 (Acrylamides)",
          "0 (KCNQ2 Potassium Channel)",
          "0 (KCNQ2 protein, human)",
          "0 (Kcnq2 protein, rat)",
          "0",
          "(N-(1-(4-cyclopropylmethyl-3,4-dihydro-2H-benzo(1,4)oxazin-6-yl)ethyl)-3-(2-fluor",
          "ophenyl)acrylamide)",
          "0 (Oxazines)",
          "0 (Potassium Channels)",
          "0 (Potassium Channels, Voltage-Gated)"
     ],
     "SB": "IM",
     "MH": [
          "Acrylamides/chemical synthesis/*pharmacology",
          "Animals",
          "Dose-Response Relationship, Drug",
          "Hippocampus/*drug effects/metabolism/pathology",
          "Humans",
          "KCNQ2 Potassium Channel",
          "Kidney/cytology/drug effects/metabolism",
          "Mice",
          "Molecular Structure",
          "Neurons/*drug effects/metabolism/pathology",
          "Oxazines/chemical synthesis/*pharmacology",
          "Patch-Clamp Techniques",
          "Potassium Channels/*drug effects/genetics/metabolism",
          "Potassium Channels, Voltage-Gated",
          "Rats",
          "Structure-Activity Relationship"
     ],
     "EDAT": "2004/03/31 05:00",
     "MHDA": "2004/11/13 09:00",
     "CRDT": [
          "2004/03/31 05:00"
     ],
     "PHST": [
          "2003/11/04 00:00 [received]",
          "2004/01/09 00:00 [revised]",
          "2004/01/14 00:00 [accepted]",
          "2004/03/31 05:00 [pubmed]",
          "2004/11/13 09:00 [medline]",
          "2004/03/31 05:00 [entrez]"
     ],
     "AID": [
          "10.1016/j.bmcl.2004.01.069 [doi]",
          "S0960894X04000812 [pii]"
     ],
     "PST": "ppublish",
     "SO": "Bioorg Med Chem Lett. 2004 Apr 19;14(8):1991-5. doi: 10.1016/j.bmcl.2004.01.069.",
     "term": "hippocampus"
}